Xcelodose microdosing Technology

At PCI, ensuring life-changing medicines reach those who need it most is our highest priority. As a truly integrated global CDMO, we are manufacturing, packaging and supply chain experts, harnessing our experience and expertise to deliver you a seamless solution with the ultimate aim of improving the lives of patients.


Traditional product development of a formulated solid oral drug for Phase I clinical trials typically involves a range of activities including initial compatibility studies, analytical method development, prototype development, short term stability, process/formulation refinement, Phase I method validation, and finally, clinical manufacture.

Xcelodose® microdosing technology removes the need for initial formulation development and the associated stability testing, enabling PCI to achieve fast times to first-in-human (FIH) studies on behalf of its clients.

The fully programmable system ensures exceptional levels of accuracy and precision whilst minimizing wastage of drug substance. We are proud to offer multiple options of microdosing technology, delivering individual
client volume requirements.

PCI has further invested in Xcelohood™ and Xceloprotect™ containment technology, further enhancing our contained solutions for the development and manufacturing of highly potent drug products.

Features of Xcelodose® Technology

Our dedicated team of specialists will be happy to discuss any of your Xcelodose microdosing Technology questions. Contact us on +1 779-208-1819 (US) or +44 1495 711 222 (UK/EU) or email talkfuture@pci.com

Xcelodose microdosing - Download this info sheet

Contact us. Get ready to experience true speed.

Rely on our Xcelodose® microdosing technology to expedite your drug product journey.


Always growing and continually advancing, we support you from early-stage development through commercialization and beyond, and with 6000+ people in 30 global GMP facilities, we are always near.